Analysts at StockNews.com initiated coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) in a research note issued on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
TRACON Pharmaceuticals Price Performance
TCON opened at $0.05 on Tuesday. TRACON Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $14.75. The stock’s 50 day moving average price is $0.09 and its 200 day moving average price is $0.69. The stock has a market cap of $154,814.00, a P/E ratio of 0.01 and a beta of 1.43.
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) EPS for the quarter. The company had revenue of $0.06 million for the quarter.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
Featured Stories
- Five stocks we like better than TRACON Pharmaceuticals
- Consumer Discretionary Stocks Explained
- What a Trump Win Looks Like for the Market Now and Into 2025
- Energy and Oil Stocks Explained
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- EV Stocks and How to Profit from Them
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
